TABLE 1.
Baseline clinical characteristics of patients receiving neoadjuvant immunotherapy
| Variable | Neoadjuvant cohort (n = 17) n (%) |
|---|---|
| Age (years) | |
| Average | 53 |
| Range | 23–80 |
| Sex | |
| Male | 9 (52.9) |
| Female | 8 (47.1) |
| Primary site | |
| Cutaneous | 14 (82.4) |
| Mucosal | 1 (5.8) |
| Unknown | 2 (11.8) |
| Pretreatment stage | |
| 3 | 15 (88.2) |
| 4 | 2 (11.8) |
| Regional/distant disease | |
| Timing | |
| Synchronous | 5 (29.4) |
| Metachronous | 12 (70.6) |
| LDH (U/l)a | |
| Average | 239 |
| Range | 120–1452 |
| BRAF status | |
| Wild type | 13 (76.5) |
| Mutantb | 4 (23.5) |
| Neoadjuvant therapy | |
| PD-1 or PD-L1 | 10 (58.8) |
| PD-1/CTLA-4 | 7 (41.2) |
| Prior therapy | |
| Targeted therapy | |
| BRAF/MEK | 3 (17.6) |
| Immunotherapy | |
| PD-1 | 1 (5.8) |
| CTLA-4 | 3 (17.6) |
| Intralesional IL-12 | 1 (5.8) |
| None | 9 (52.9) |
a
Serum lactate dehydrogenase, normal range 105–333 U/L
b
Refers to V600E or V600K mutation